Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 251–275 of 1,004 studies in Prevention and risk (page 11 of 41) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention and risk” covers

Prevention and risk — What might lower the risk of dementia — and what happened when those things were properly tested.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

This meta-analysis suggests that hearing impairment is associated with cognitive problems. 5 key findings →

Design: systematic review Participants: 602 Evidence: high

Nineteen cross-sectional studies that investigated 19.734 community-dwelling and institutionalized older adults free of disability and dementia were included. 5 key findings →

Design: systematic review Evidence: high

Stroke, dementia, and hypertension are associated with late-onset epilepsy; however, the role of other vascular and lifestyle factors remains unclear. 5 key findings →

Design: cohort study Participants: 792 Evidence: moderate

Rationale and Design of the Hamburg City Health Study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. European journal of epidemiology 2019-11-08

The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several important risk and prognostic factors in major chronic diseases. 1 key finding →

Design: cohort study Participants: 45,000 Evidence: moderate

Broad consensus emerged on the protective role against dementia of leisure activities. 3 key findings →

Design: systematic review Participants: 26 Evidence: high

Fentanyl Test Strip Use and Overdose Risk Reduction Behaviors Among People Who Use Drugs

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-05-13

The study included 732 participants (median [IQR] age, 41 [34.0-48.0] years; 369 [50.4%] male; 64 [8.9%] Black or African American, 587 [81.3%] White, and 71 [9.8%] other races); 414 reported baseline FTS use and 318 did not. 5 key findings →

Design: cohort study Participants: 732 Evidence: moderate

Hearing Loss, Brain Structure, Cognition, and Dementia Risk in the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-11-05

Sample 1 included 1656 participants (mean [range] age, 58.1 [29.7-85.6] years; 903 female [54.5%]), and sample 2 included 935 participants (mean [range] age, 67.6 [60.0-85.6] years; 518 female [55.4%]). 4 key findings →

Design: cohort study Participants: 1,656 Evidence: moderate

Adherence to the Mediterranean Diet and Obesity-Linked Cancer Risk in EPIC

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2025-02-25

A total of 450 111 participants were included in the study (mean [SD] age, 51.1 [9.8] years; 70.8% women) and followed up during a median (IQR) time of 14.9 (4.1) years. 5 key findings →

Design: cohort study Participants: 111 Evidence: moderate

Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Neurology 2025-04-14

Of the 14 685 participants (7355 female [50%] and 7330 male [50%]; mean [SD] age, 73.8 [8.5] years) who met the inclusion criteria, 221 participants (1.5%) developed LOE during follow-up. 5 key findings →

Design: longitudinal study Participants: 713 Evidence: moderate

No significant difference between the three groups in ADAS-Cog was found at the primary endpoint at 15 months (CPR vs health advice, β= -0·04 [95% CI -0·34 to 0·26]; RFM vs health advice, β= -0·14 [-0·44 to 0·15]; CPR vs RFM, β=0·10 [-0·19 to 0·40]) nor at the 6-month and 12-month follow-ups. 1 key finding →

Design: RCT Participants: 456 Evidence: null result

Metformin might correlate with a lower dementia incidence in people with T2DM. 4 key findings →

Design: meta-analysis Participants: 3,463,100 Evidence: early

Physical activity and risk of cognitive impairment and dementia in elderly persons

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Archives of neurology 2001-03-01

Regular physical activity could represent an important and potent protective factor for cognitive decline and dementia in elderly persons. 3 key findings →

Design: cohort study Evidence: moderate

For the last 17 years, an increase of mortality for patients with hip fracture and a higher mortality rate in men than in women were observed. 5 key findings →

Design: cohort study Participants: 3,992 Evidence: moderate

At baseline, 4,463 subjects were without dementia, 836 of whom had HL. 3 key findings →

Design: cohort study Participants: 4,463 Evidence: moderate

There is an urgent need to identify lifestyle activities that reduce functional decline and dementia associated with population aging. 5 key findings →

Design: randomized controlled trial Evidence: high

Forty-one studies were included. 2 key findings →

Design: meta-analysis Evidence: high

Our study has identified not only risk factors associated with functional decline but also the interactions among these factors. 5 key findings →

Design: cohort study Evidence: moderate

Systematic review of the literature using the American Academy of Neurology's evidence-based methods. 2 key findings →

Design: systematic review Evidence: high

Alzheimer's dementia affects more than 40 million people worldwide with substantial increases in prevalence anticipated. 1 key finding →

Design: cohort study Participants: 24,000 Evidence: moderate

These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. 5 key findings →

Design: meta-analysis Evidence: high

A team applying comprehensive geriatric assessment and rehabilitation, including prevention, detection, and treatment of fall risk factors, can successfully prevent inpatient falls and injuries, even in patients with dementia. 2 key findings →

Participants: 199 Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed